SCHEMBL5501477

SCHEMBL5501477

COc1cc2cncnc2cc1OCCn1ccnn1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 5/20 0.52
FGFR1 P11362 4/20 0.52
FLT1 P17948 4/20 0.52
FGFR2 P21802 4/20 0.52
FGFR3 P22607 4/20 0.52
FLT4 P35916 4/20 0.52
KDR P35968 4/20 0.52
PDGFRB P09619 8/20 0.50
EGFR P00533 3/20 0.50
SRC P12931 1/20 0.41
ENPP1 P22413 1/20 0.38
PDGFRA P16234 3/20 0.38
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
EHMT2 Q96KQ7 1/20 0.35
EHMT1 Q9H9B1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5493929 0.80 ENPP1 (0.64) FGFR4FGFR1FLT1FGFR2FGFR3
SCHEMBL6000263 0.78 EGFR (0.46) FGFR4FGFR1FLT1KDREGFR
SCHEMBL30000483 0.78 ENPP1 (0.59) FGFR4PDGFRBEGFRENPP1PDGFRA
SCHEMBL241727 0.77 EGFR (0.58) FGFR4PDGFRBEGFRPDGFRAKDM4E
SCHEMBL30001048 0.77 EGFR (0.45) FGFR4PDGFRBEGFRENPP1PDGFRA
SCHEMBL5682691 0.77 ENPP1 (0.48) FGFR4PDGFRBEGFRENPP1PDGFRA
SCHEMBL30000368 0.77 EGFR (0.45) FGFR4PDGFRBEGFRENPP1PDGFRA
SCHEMBL30001229 0.77 EGFR (0.45) FGFR4PDGFRBEGFRENPP1PDGFRA
SCHEMBL30864339 0.77 ENPP1 (0.48) FGFR4PDGFRBEGFRENPP1PDGFRA
SCHEMBL5678927 0.77 ENPP1 (0.48) FGFR4PDGFRBEGFRENPP1PDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262201-B1 For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals ASTRAZENECA AB (SE) 2007-08-28 US disclosed
EP-1005470-B1 OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2007-08-01 EP disclosed
EP-1119567-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2005-05-04 EP disclosed
US-6294532-B1 TREATMENT OF A NUMBER OF DISEASE STATES INCLUDING CANCER AND RHEUMATOID ARTHRITIS. ZENECA LIMITED (GB) 2001-09-25 US disclosed
EP-1119567-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2001-08-01 EP disclosed
EP-1005470-A1 OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ZENECA LIMITED (GB) 2000-06-07 EP disclosed
WO-2000021955-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2000-04-20 WO disclosed
WO-1999010349-A1 OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ZENECA LIMITED (GB) 1999-03-04 WO disclosed